当前位置: X-MOL 学术Expert Rev. Clin. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Teprotumumab for the treatment of thyroid eye disease.
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2020-08-09 , DOI: 10.1080/1744666x.2020.1801421
Yongjing Ju 1 , Junyi Yang 1
Affiliation  

ABSTRACT

Introduction

Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease.

Areas covered

The authors performed a systematic review of the literature using the PubMed database, and the following keywords were used: ‘teprotumumab,’ ‘thyroid eye disease,’ and ‘insulin-like growth factor I receptor.’ The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of teprotumumab were introduced in this paper.

Expert opinion

Teprotumumab is a human monoclonal antibody targeting insulin-like growth factor-I receptor. Clinical trials indicated that proptosis response of teprotumumab was 83%, and clinical activity score, diplopia, and quality of life were also better than placebo. Teprotumumab was well tolerated, common adverse reactions included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.



中文翻译:

Teprotumumab 用于治疗甲状腺眼病。

摘要

介绍

甲状腺眼病是一种使人衰弱、毁容和可能致盲的眼周疾病。Teprotumumab 是一种人胰岛素样生长因子-I 受体单克隆抑制剂抗体,适用于治疗甲状腺眼病。

覆盖区域

作者使用 PubMed 数据库对文献进行了系统审查,并使用了以下关键词:“teprotumumab”、“甲状腺眼病”和“胰岛素样生长因子 I 受体”。本文介绍了teprotumumab的化学性质、作用机制、药代动力学、临床疗效和安全性。

专家意见

Teprotumumab 是一种靶向胰岛素样生长因子-I 受体的人单克隆抗体。临床试验表明,teprotumumab 的眼球突出反应率为 83%,临床活动评分、复视和生活质量也优于安慰剂。Teprotumumab 耐受性良好,常见不良反应包括肌肉痉挛、恶心、脱发、腹泻、疲劳、高血糖、听力障碍、味觉障碍、头痛和皮肤干燥。

更新日期:2020-10-12
down
wechat
bug